血清学指标诊断肝纤维化的研究进展
Research Progress of Serological Index in Diagnosis of Liver Fibrosis
DOI: 10.12677/MD.2022.122014, PDF,    科研立项经费支持
作者: 张 引, 解 琴, 尤丽英*:昆明医科大学附属甘美医院,云南 昆明
关键词: 肝活检血清学指标慢性肝病肝纤维化Liver Biopsy Serological Indicators Chronic Liver Disease Liver Fibrosis
摘要: 不同病因所致的慢性肝病(chronic Liver Disease,CLD)正在逐渐危害我们人类的生命健康,如果不及时进行干预,最终会引起肝脏纤维化、肝硬化、肝癌甚至死亡。肝纤维化的形成和积累是导致发展性肝病的常见途径;所以,临床上早期发现、早期诊断肝纤维化对于临床实践中患者的管理至关重要。目前临床上诊断肝纤维化的“金标准”是肝活检,然而“金标准”也并非完美无缺,存在一定风险,比如:侵袭性、采样误差、并发症(出血、感染等)、重复性差、不利于动态观察病情变化等。为了更好的避开这些弊端,减轻患者的痛苦、经济负担、社会负担以及改善患者的生活质量,一些易于计算的血清学诊断模型应运而生,给患者带来了福音,也给临床医生带来了极大的便利,便于动态观察纤维化程度,动态观察患者病情变化。迄今为止已有肝纤4项、数个无创诊断模型、蛋白质等血清学指标在慢性肝病、肝纤维化患者中得到评价。本文就血清学无创指标诊断肝纤维化的研究进展做一综述。
Abstract: Chronic liver disease (CLD) caused by different etiologies is gradually endangering the life and health of human beings. Without timely intervention, it will eventually cause liver fibrosis, cirrhosis, liver cancer and even death. The formation and accumulation of liver fibrosis is a common pathway leading to developmental liver disease. Therefore, early detection and diagnosis of liver fibrosis in clinical practice is of great importance to the management of patients. At present, the “gold standard” for clinical diagnosis of liver fibrosis is liver biopsy. However, the “gold standard” is not perfect, and there are certain risks, such as: invasiveness, sampling error, complications (bleeding, infection, etc.), poor repeatability, not conducive to dynamic observation of disease changes, etc. In order to avoid these disadvantages, the patient's pain, to reduce the economic burden and social burden and improve the patient’s quality of life, some is easy to calculate the serological diagnosis model arises at the historic moment, brought the Gospel to patients, also has brought great convenience for clinicians, easy to dynamically observe the degree of fibrosis, dynamic observation of patients condition change. So far, four hepatic fibrosis items, several non-invasive diagnostic models, protein and other serological indicators have been evaluated in patients with chronic liver disease and liver fibrosis. This article reviews the research progress of serological noninvasive indexes in the diagnosis of liver fibrosis.
文章引用:张引, 解琴, 尤丽英. 血清学指标诊断肝纤维化的研究进展[J]. 医学诊断, 2022, 12(2): 89-94. https://doi.org/10.12677/MD.2022.122014

参考文献

[1] Oguzhanoglu, A., Tülay, K., Ortaç, R. and Bülent, T. (2014) Cellular and Molecular Mechanisms in Liver Fibrogenesis. Archives of Biochemistry and Biophysics, 548, 20-37. [Google Scholar] [CrossRef] [PubMed]
[2] 任蓓蓓, 杨婧, 安文慧, 郑杰, 杨秋瑾. 瞬时弹性成像在慢性肝病中的临床应用进展[J]. 中国现代医药杂志, 2020, 22(2): 89-93.
[3] 沈斐斐, 陆伦根. 瞬时弹性成像技术在慢性肝病肝纤维化诊断中的应用进展[J]. 实用肝脏病杂志, 2016, 19(5): 620-623.
[4] Weiskirchen, R. and Tacke, F. (2016) Liver Fibrosis: From Pathogenesis to Novel Therapies. Digestive Diseases, 34, 410-422. [Google Scholar] [CrossRef] [PubMed]
[5] 聂青和. 肝纤维化的逆转策略及研究现状[J]. 世界华人消化杂志, 2005, 13(10): 1165-1174.
[6] 沈鼎明. 肝纤维化的发生机制[J]. 中华肝脏病杂志, 2000, 8(4): 241.
[7] 黄艳, 黄成, 李俊. 肝纤维化病程中Kupffer细胞分泌的细胞因子对肝星状细胞活化增殖、凋亡的调控[J]. 中国药理学通报, 2010, 26(1): 9-13.
[8] 凌文武, 卢强, 邱婷婷, 罗燕. 肝纤维化的超声诊断应用进展[J]. 四川医学, 2017, 38(5): 585-588.
[9] 张悦, 粟兴洋, 谢静怡, 潘珏, 纪泛扑. 《欧洲肝病学会临床实践指南: 评估肝脏疾病严重程度及预后的无创检测(2021年更新)》摘译[J]. 临床肝胆病杂志, 2021, 37(11): 2550-2554.
[10] Sebastiani, G., Ghali, P., Wong, P., Klein, M.B., Deschenes, M. and Myers, R.P. (2014) Physicians’ Practices for Diagnosing Liver Fibrosis in Chronic Liver Diseases: A Nationwide, Canadian Survey. Canadian Journal of Gastroenterology and Hepatology, 28, 23-30. [Google Scholar] [CrossRef] [PubMed]
[11] 杨二娜, 曹武奎. 肝纤维化无创诊断的研究进展[J]. 临床肝胆病杂志, 2017, 33(11): 2209-2213.
[12] 盖美茹, 张华珍, 程爱玲, 张国强. 肝纤维化血清学指标与病毒性肝炎肝功能损害程度的关系[J]. 中国全科医学, 2003, 6(10): 824-825.
[13] 李宝, 王登峰, 孙彦峰. 不同类型人群血清中肝纤维四项检测结果分析[J]. 临床医学研究与实践, 2020, 5(17): 105-106 + 109-109.
[14] 庄云英, 张海燕, 曾清芳. 慢性乙型肝炎肝纤维化的无创诊断研究进展[J]. 肝脏, 2021, 26(1): 84-87.
[15] 张波克, 周导, 朱俊, 等. 血清肝纤维化四项在肝豆状核变性肝硬化进展中的变化及临床价值[J]. 中国临床研究, 2020, 33(7): 900-903.
[16] 贾海英, 郭淑丽, 王玲玲, 黄睿, 黄国虹, 王昌敏. 血清肝纤维化指标在慢性乙型肝炎不同阶段中的对比分析[J]. 实验与检验医学, 2020, 38(6): 1077-1078 + 1103-1103.
[17] 赵佳强, 路佳益, 张振林. 对肝纤维化过程中相关指标的研究探讨[J]. 保健文汇, 2020(12): 226-227.
[18] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年) [J]. 临床肝胆病杂志, 2019, 35(10): 2163-2172.
[19] Wai, C.T., Greenson, J.K., Fontana, R.J., et al. (2003) A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients with Chronic Hepatitis C. Hepatology, 38, 518-526. [Google Scholar] [CrossRef] [PubMed]
[20] Giada, S., Alessandro, V., Maria, G. and Alfredo, A. (2007) Sequential Algorithms Combining Non-Invasive Markers and Biopsy for the Assessment of Liver Fibrosis in Chronic Hepatitis B. World Journal of Gastroenterology, 13, 525-531. [Google Scholar] [CrossRef] [PubMed]
[21] Jin, W.W., Lin, Z.H., Xin, Y.N., Jiang, X.J., Dong, Q.J. and Xuan, S.Y. (2012) Diagnostic Accuracy of the Aspartate Aminotransferase-to-Platelet Ratio Index for the Prediction of Hepatitis B-Related Fibrosis: A Leading Meta-Analysis. BioMed Central, 12, Article No. 14. [Google Scholar] [CrossRef
[22] 陆伦根, 曾民德. 肝纤维化的诊断和评估[J]. 中华肝脏病杂志, 2005, 13(8): 603-604.
[23] Richard, K.S., Lissen, E., Clumeck, N., et al. (2006) Development of a Simple Noninvasive Index to Predict Significant Fibrosis in Patients with HIV/HCV Coinfection. Hepatology (Baltimore, Md.), 43, 1317-1325. [Google Scholar] [CrossRef] [PubMed]
[24] Kim, B.K., Kim, D.Y., Park, J.Y., et al. (2010) Validation of FIB-4 and Comparison with Other Simple Noninvasive Indices for Predicting Liver Fibrosis and Cirrhosis in Hepatitis B Virus-Infected Patients. Liver International, 30, 546-553. [Google Scholar] [CrossRef] [PubMed]
[25] Cross, T.J., Rizzi, P., Berry, P.A., Bruce, M., Portmann, B. and Harrison, P.M. (2009) King’s Score: An Accurate Marker of Cirrhosis in Chronic Hepatitis C. European Journal of Gastroenterology & Hepatology, 21, 730-738. [Google Scholar] [CrossRef
[26] Keyur, P. Giada, S. (2020) Limitations of Non-Invasive Tests for Assessment of Liver Fibrosis. JHEP Reports, 2, Article ID: 100067. [Google Scholar] [CrossRef] [PubMed]
[27] 高楠, 杨若男, 孟真, 王万海. 无创肝纤维化检测结果与慢性乙型肝炎肝纤维化程度的相关研究[J]. 东南大学学报(医学版), 2019, 38(2): 269-273.
[28] Lemoine, M., Shimakawa, Y., Nayagam, S., et al. (2016) The Gamma-Glutamyl Transpeptidase to Platelet Ratio (GPR) Predicts Significant Liver Fibrosis and Cirrhosis in Patients with Chronic HBV Infection in West Africa. Gut, 65, 1369-1376. [Google Scholar] [CrossRef] [PubMed]
[29] 王海莉, 贾因棠. APRI、GPRI、FIB-4在诊断慢乙肝肝脏纤维化及肝癌中的临床应用价值[J]. 山西医科大学学报, 2018, 49(6): 650-654.
[30] Zhou, K., Gao, C.F., Zhao, Y.P., et al. (2010) Simpler Score of Routine Laboratory Tests Predicts Liver Fibrosis in Patients with Chronic Hepatitis B. Journal of Gastroenterology and Hepatology, 25, 1569-1577. [Google Scholar] [CrossRef] [PubMed]
[31] Forns, X., Ampurdanès, S., Llovet, J.M., et al. (2002) Identification of Chronic Hepatitis C Patients without Hepatic Fibrosis by a Simple Predictive Model. Hepatology, 36, 986-992. [Google Scholar] [CrossRef] [PubMed]
[32] 刘红虹, 福军亮, 洪智贤, 等. 肝纤维化血清学无创检测研究进展[J]. 传染病信息, 2021, 34(4): 347-352.
[33] Kladney, R.D. (2000) GP73, a Novel Golgi-Localized Protein Upregulated by Viral Infection. Gene, 249, 53-65. [Google Scholar] [CrossRef
[34] 罗双艳, 钟丽坤, 张国, 蒋长秀, 宋怀宇. 血清高尔基体蛋白73、血清诊断模型APRI及声辐射力脉冲成像技术在慢性乙型肝炎患者肝纤维化程度评估中的价值[J]. 广西医学, 2020, 42(5): 525-528.
[35] 李佳娜, 郑瑞琦, 李娜, 胡玉琳. 高尔基体蛋白73的生物学特征及在肝纤维化和肝硬化中的诊断价值[J]. 临床肝胆病杂志, 2019, 35(6): 1361-1364.
[36] 李莉, 李淑敏, 张志涛, 赵杰. 血清学指标联合瞬时弹性成像对乙肝肝纤维化及食管静脉曲张程度的诊断价值[J]. 浙江医学, 2019, 41(1): 63-66.
[37] 刘芳, 魏琳, 王珊珊, 黄斌. 瞬时弹性成像技术联合血清学指标对慢性乙型肝炎肝纤维化的诊断价值研究[J]. 中国全科医学, 2016, 19(25): 3039-3044.